FI3334761T3 - Vasta-ainepohjaisia molekyylejä, jotka ovat selektiivisiä Taun {p}Ser404-epitoopille, ja niiden käyttöjä tauopatian diagnosoinnissa ja hoidossa - Google Patents
Vasta-ainepohjaisia molekyylejä, jotka ovat selektiivisiä Taun {p}Ser404-epitoopille, ja niiden käyttöjä tauopatian diagnosoinnissa ja hoidossa Download PDFInfo
- Publication number
- FI3334761T3 FI3334761T3 FIEP16835899.2T FI16835899T FI3334761T3 FI 3334761 T3 FI3334761 T3 FI 3334761T3 FI 16835899 T FI16835899 T FI 16835899T FI 3334761 T3 FI3334761 T3 FI 3334761T3
- Authority
- FI
- Finland
- Prior art keywords
- disease
- dementia
- patient
- molecule
- pick
- Prior art date
Links
- 208000034799 Tauopathies Diseases 0.000 title claims 8
- 238000003745 diagnosis Methods 0.000 title claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 11
- 206010012289 Dementia Diseases 0.000 claims 8
- 208000017004 dementia pugilistica Diseases 0.000 claims 8
- 208000024827 Alzheimer disease Diseases 0.000 claims 7
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 102000013498 tau Proteins Human genes 0.000 claims 6
- 108010026424 tau Proteins Proteins 0.000 claims 6
- 150000001413 amino acids Chemical group 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 230000000750 progressive effect Effects 0.000 claims 5
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims 4
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 4
- 201000010374 Down Syndrome Diseases 0.000 claims 4
- 206010018341 Gliosis Diseases 0.000 claims 4
- 208000027089 Parkinsonian disease Diseases 0.000 claims 4
- 206010034010 Parkinsonism Diseases 0.000 claims 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 4
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 230000002308 calcification Effects 0.000 claims 4
- 210000000349 chromosome Anatomy 0.000 claims 4
- 230000007387 gliosis Effects 0.000 claims 4
- 230000002739 subcortical effect Effects 0.000 claims 4
- 230000009529 traumatic brain injury Effects 0.000 claims 4
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 3
- 208000026072 Motor neurone disease Diseases 0.000 claims 3
- 208000010577 Niemann-Pick disease type C Diseases 0.000 claims 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 3
- 208000005264 motor neuron disease Diseases 0.000 claims 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 3
- 206010044688 Trisomy 21 Diseases 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 238000003384 imaging method Methods 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 208000006212 Alzheimer disease 16 Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000002161 motor neuron Anatomy 0.000 claims 1
- 210000004126 nerve fiber Anatomy 0.000 claims 1
- 230000005298 paramagnetic effect Effects 0.000 claims 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical class OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562204711P | 2015-08-13 | 2015-08-13 | |
| PCT/US2016/046520 WO2017027691A1 (en) | 2015-08-13 | 2016-08-11 | Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3334761T3 true FI3334761T3 (fi) | 2023-08-14 |
Family
ID=57984105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP16835899.2T FI3334761T3 (fi) | 2015-08-13 | 2016-08-11 | Vasta-ainepohjaisia molekyylejä, jotka ovat selektiivisiä Taun {p}Ser404-epitoopille, ja niiden käyttöjä tauopatian diagnosoinnissa ja hoidossa |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10358503B2 (enExample) |
| EP (1) | EP3334761B1 (enExample) |
| JP (1) | JP6913077B2 (enExample) |
| CN (1) | CN108137679B (enExample) |
| ES (1) | ES2954969T3 (enExample) |
| FI (1) | FI3334761T3 (enExample) |
| PT (1) | PT3334761T (enExample) |
| WO (1) | WO2017027691A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190134997A (ko) | 2017-02-17 | 2019-12-05 | 데날리 테라퓨틱스 인크. | 항-tau 항체 및 이의 사용 방법 |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| WO2019227490A1 (en) * | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
| WO2020123492A1 (en) * | 2018-12-10 | 2020-06-18 | New York University | Monoclonal antibodies targeting c-terminal region of phosphorylated tau |
| CN110028583B (zh) * | 2019-05-07 | 2020-09-11 | 温州医科大学 | 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用 |
| CA3137882A1 (en) * | 2019-05-23 | 2020-11-26 | Tamara SEREDENINA | Anti-tdp-43 binding molecules and uses thereof |
| US12281166B2 (en) | 2020-05-26 | 2025-04-22 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
| WO2024192429A1 (en) * | 2023-03-16 | 2024-09-19 | Abbvie Inc. | Assay for evaluating tau propagation |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| WO1991001754A1 (en) | 1989-08-09 | 1991-02-21 | Rhodes Buck A | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| JPH06508880A (ja) | 1991-07-08 | 1994-10-06 | ユニバーシティ オブ マサチューセッツ アット アムハースト | サーモトロピック液晶セグメント化ブロックコポリマー |
| ATE193301T1 (de) | 1993-03-09 | 2000-06-15 | Genzyme Corp | Verfahren zur isolierung von proteinen aus milch |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| MXPA01007895A (es) | 1999-02-03 | 2003-07-21 | Biosante Pharmaceuticals Inc | Particulas terapeuticas de fosfato de calcio, metodos de manufactura y usos. |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| HK1049014A1 (zh) | 1999-07-29 | 2003-04-25 | Medarex, Inc. | 抗her2/neu的人类单克隆抗体 |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| DK1354034T3 (da) | 2000-11-30 | 2008-03-25 | Medarex Inc | Transgene transchromosomale gnavere til fremstilling af humane antistoffer |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| EP4218794A3 (en) | 2009-06-10 | 2023-09-13 | New York University | Immunological targeting of pathological tau proteins |
| DK2625198T3 (en) | 2010-10-07 | 2015-09-28 | Ac Immune Sa | Antibodies that recognize the phosphorylated tau |
| JP6358953B2 (ja) * | 2011-10-07 | 2018-07-18 | エーシー イミューン エス．エー． | タウを認識するホスホ特異的抗体 |
| WO2014008404A1 (en) * | 2012-07-03 | 2014-01-09 | Washington University | Antibodies to tau |
| JP6290212B2 (ja) * | 2012-08-16 | 2018-03-07 | アイピエリアン，インコーポレイティド | タウオパチーの処置方法 |
| WO2014059442A2 (en) * | 2012-10-12 | 2014-04-17 | Arizona Board Agents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Antibody based reagents that specifically recognize toxic oligomeric forms of tau |
| US10132818B2 (en) | 2014-07-08 | 2018-11-20 | New York University | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| CN204439640U (zh) * | 2014-12-12 | 2015-07-01 | 北京海略世纪生物技术有限责任公司 | 一种新型筛查用老年痴呆速测试剂盒 |
-
2016
- 2016-08-11 FI FIEP16835899.2T patent/FI3334761T3/fi active
- 2016-08-11 US US15/750,982 patent/US10358503B2/en active Active
- 2016-08-11 JP JP2018507002A patent/JP6913077B2/ja active Active
- 2016-08-11 EP EP16835899.2A patent/EP3334761B1/en active Active
- 2016-08-11 CN CN201680057424.9A patent/CN108137679B/zh active Active
- 2016-08-11 PT PT168358992T patent/PT3334761T/pt unknown
- 2016-08-11 ES ES16835899T patent/ES2954969T3/es active Active
- 2016-08-11 WO PCT/US2016/046520 patent/WO2017027691A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP3334761A1 (en) | 2018-06-20 |
| CN108137679B (zh) | 2022-07-19 |
| HK1250729A1 (zh) | 2019-01-11 |
| US10358503B2 (en) | 2019-07-23 |
| JP2018535921A (ja) | 2018-12-06 |
| WO2017027691A1 (en) | 2017-02-16 |
| JP6913077B2 (ja) | 2021-08-04 |
| EP3334761A4 (en) | 2019-04-24 |
| PT3334761T (pt) | 2023-08-17 |
| EP3334761B1 (en) | 2023-07-19 |
| ES2954969T3 (es) | 2023-11-27 |
| CN108137679A (zh) | 2018-06-08 |
| US20180312608A1 (en) | 2018-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3334761T3 (fi) | Vasta-ainepohjaisia molekyylejä, jotka ovat selektiivisiä Taun {p}Ser404-epitoopille, ja niiden käyttöjä tauopatian diagnosoinnissa ja hoidossa | |
| Öhrfelt et al. | Cerebrospinal fluid α-synuclein in neurodegenerative disorders—a marker of synapse loss? | |
| Sillen et al. | NMR investigation of the interaction between the neuronal protein tau and the microtubules | |
| CN109496272B (zh) | α-突触核蛋白检测测定法和用于诊断α-突触核蛋白病的方法 | |
| JP2017532288A5 (enExample) | ||
| KR102448128B1 (ko) | 미스폴딩된 단백질의 검출 | |
| US9464118B2 (en) | Polymers containing multivalent amyloid-beta-binding D-peptides and their use | |
| JP2018534236A5 (enExample) | ||
| JP2014503178A5 (enExample) | ||
| US20160077110A1 (en) | Detection of Misfolded Amyloid Beta Protein | |
| JP2015505665A5 (enExample) | ||
| JP2018535921A5 (enExample) | ||
| O’Hara et al. | Methods for detecting toxic α-synuclein species as a biomarker for Parkinson’s disease | |
| ES3016783T3 (en) | Method for the preselection of drugs for protein misfolding diseases | |
| JP2020023510A (ja) | アミロイドベータ結合性環状ペプチドおよびその使用 | |
| CN104380110A (zh) | 处理血液、血液产品和器官的方法 | |
| IL270612B2 (en) | Discovery of misfolded tau protein | |
| Wei et al. | Differential neuropsychiatric associations of plasma biomarkers in older adults with major depression and subjective cognitive decline | |
| Abdul‐Rahman et al. | The potential of phosphorylated α‐synuclein as a biomarker for the diagnosis and monitoring of multiple system atrophy | |
| Pellkofer et al. | Evaluation of the methoxy-X04 derivative BSC4090 for diagnosis of prodromal and early Alzheimer’s disease from bioptic olfactory mucosa | |
| US9964547B2 (en) | Method for detecting aSyn-specific antibodies in a biological sample | |
| Taverna et al. | Probing the effect of the molecular interface of gold nanoparticles on the disassembly of insulin amyloid fibrils | |
| E. Rojo et al. | Molecular targets in the rational design of AD specific PET tracers: tau or amyloid aggregates? | |
| Mukhamedyarov et al. | State-of-the-Art Technologies for Studying Cellular and Molecular Mechanisms Underlying Alzheimer's Disease | |
| JP7296136B2 (ja) | タウオパチーの治療薬または予防薬のスクリーニング方法およびタウオパチーの診断方法 |